KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash & Equivalents (2020 - 2026)

AbCellera Biologics filings provide 7 years of Cash & Equivalents readings, the most recent being $77.1 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 87.27% to $77.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $77.1 million through Mar 2026, down 87.27% year-over-year, with the annual reading at $533.8 million for FY2025, 14.67% down from the prior year.
  • Cash & Equivalents hit $77.1 million in Q1 2026 for AbCellera Biologics, down from $533.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $886.5 million in Q4 2022 and bottomed at $77.1 million in Q1 2026.
  • Average Cash & Equivalents over 5 years is $489.9 million, with a median of $545.7 million recorded in 2022.
  • The largest annual shift saw Cash & Equivalents soared 369.26% in 2024 before it tumbled 87.27% in 2026.
  • AbCellera Biologics' Cash & Equivalents stood at $886.5 million in 2022, then plummeted by 84.96% to $133.3 million in 2023, then soared by 369.26% to $625.6 million in 2024, then decreased by 14.67% to $533.8 million in 2025, then crashed by 85.56% to $77.1 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Cash & Equivalents are $77.1 million (Q1 2026), $533.8 million (Q4 2025), and $495.7 million (Q3 2025).